Zoonotic Disease Treatment Market Outlook 2031:
The global zoonotic disease treatment market size was valued at USD 39.01 Billion in 2022 and is projected to reach USD 65.35 Billion by 2031, expanding at a CAGR of 5.9% during the forecast period 2023 - 2031, attributed to increasing demand and consumption of meat, dairy, and poultry products as the population base is increasing continuously. Moreover, the market expansion is further escalated due to rising ownership of pets worldwide.
Zoonotic can be understood as types of diseases that spread from animals or insects to humans and vice-versa. Zoonotic is also widely known as zoonosis. Some of the diseases do not have any impact on humans while others can make them sick which can be for a short-term illness or can be crucial diseases such as plague, rabies, and others.
There are several ways in which the diseases can be transmitted from one individual to another that include oral absorption, direct interaction, by air, and by pests. The illness, caused by wiretaps, can lead to major health issues and can even cause death.
As per the estimations by World Small Animal Veterinary Association (WSAVA), it was estimated that 70% to 80% of animal-transmitted diseases belonged to zoonotic diseases.
A handful of organizations are currently working towards the significance of conducting researches to ensure its identification, control, and prevention from spreading. For instance, an endemic zoonotic disease named Rift Valley Fever occurred in Middle East & Africa and the cost for prevention was expected to be about USD 427 million every year.
Zoonotic Disease Treatment Market Trends, Drivers, Restraints, and Opportunities
- Wide prevalence of infectious diseases in animals is anticipated to fuel the market growth during the forecast period.
- Advancements in technology for the development of new drugs for such diseases are expected to propel market growth in the coming years.
- Increasing global population and movement of a large number of the population from one country to another is another driving factor in the growth expansion during the forecast period.
- Lack of awareness among people regarding such diseases, high cost of medicines, and strict regulations by the government are expected to act as key restraining points that can hinder the market growth in the coming years.
- Ongoing research & development programs for the development of new zoonotic disease therapeutics across the globe are estimated to present key opportunities for the market expansion in the long run.
Scope of the Zoonotic Disease Treatment Market Report
The report on the global zoonotic disease treatment market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Zoonotic Disease Treatment Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Causes (Bacteria, Virus, Rodents, Ticks, Nematode, and Others), Types of Sickness (Tuberculosis, Malaria, Rabies, Viral Hepatitis, Relapsing Fever, and Others), Types of Medications (Antibacterial Medication, Antibiotics, Antifungal Medications, and Others), and End-users (Hospitals and Clinics)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
BioCryst Pharmaceuticals, Inc.; Glaxo SmithKline; Johnson & Johnson; Sanofi S.A.; Pfizer, Inc.; F Hoffmann-La Roche Inc.; Novartis; and AstraZeneca
|
Zoonotic Disease Treatment Market Segment Insights
Virus segment is projected to account for a large market share
Based on causes, the global zoonotic disease treatment market is categorized as bacteria, virus, rodents, ticks, nematode, and others. The virus segment is projected to account for a large market share during the projected period owing to wide prevalence of the viral infection and other diseases associated with virus. Moreover, high treatment expenses of the patients presents a key driver of the segment growth.
Malaria segment is anticipated to expand at a high CAGR
On the basis of types of sickness, the market is segregated into tuberculosis, malaria, rabies, viral hepatitis, relapsing fever, and others. The malaria segment is anticipated to expand at a high CAGR during the forecast period due to widespread occurrence of the disease especially in Africa and other regions.
Moreover, the growing investment in the field of R&D related to the disease is expected to boost the market segment in the coming years.
Antibiotics segment is projected to grow rapidly
In terms of types of medications, the global zoonotic disease treatment market is segregated into antibacterial medication, antibiotics, antifungal medications, and others.
The antibiotics segment is projected to grow rapidly in the coming years owing to wide demand for the medications due to rising cases of various infectious diseases. However, the antibacterial medications is anticipated to constitute a key market share during the targeted period owing to wide availability of medicines.
Hospitals segment is expected to hold a major share of the market
On the basis of end-users, the market is bifurcated into hospitals and clinics. The hospitals segment is expected to hold a major share of the market in the coming years attributed to the necessity of healthcare set-ups that are innovative and lower in price.
Furthermore, the availability of advanced treatment devices and the presence of specialized doctors are major factors driving the segment growth.
North America is anticipate to dominate the market
In terms of regions, the global zoonotic disease treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period attributed to the presence of improved healthcare expenditures and the availability of innovative healthcare facilities in the region.
On the other hand, the market of regions such as Asia Pacific and Middle East & Africa are projected to grow at a substantial rate in the coming years owing to wide prevalence of the zoonotic disease especially due to lack of availability of safe drinking water in many parts of these regions.
Segments
The global zoonotic disease treatment market has been segmented on the basis of
Causes
- Bacteria
- Virus
- Rodents
- Ticks
- Nematode
- Others
Types of Sickness
- Tuberculosis
- Malaria
- Rabies
- Viral Hepatitis
- Relapsing Fever
- Others
Types of Medications
- Antibacterial Medication
- Antibiotics
- Antifungal Medications
- Others
End-users
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- BioCryst Pharmaceuticals, Inc.
- Glaxo SmithKline
- Johnson & Johnson
- Sanofi S.A.
- Pfizer, Inc.
- F Hoffmann-La Roche Inc.
- Novartis
- AstraZeneca
Competitive Landscape
Key players competing in the global zoonotic disease treatment market are BioCryst Pharmaceuticals, Inc.; Glaxo SmithKline; Johnson & Johnson; Sanofi S.A.; Pfizer, Inc.; F Hoffmann-La Roche Inc.; Novartis; and AstraZeneca.
Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, partnerships, mergers, and production capacity expansion in order to increase their expansion, their consumer base, and market position globally.
Request For Customization
Enquiry Before Buying
Speak With Analyst
